Evaluation of the EF192B Protection Versus No Treatment

Exclusion Criteria

• •Diagnosis of skin diseases such as vitiligo, psoriasis, atopic dermatitis.
• •Diagnosis of immunological insufficiency.
• •Use of systemic corticosteroids or immunosuppressants.
• •Diagnosis of type 1 diabetes mellitus or insulin-dependent diabetes or presence of complications resulting from diabetes (such as retinopathy, nephropathy, neuropathy), presence of diabetes-related dermatoses (such as plantar ulcers, lipoid necrobiosis, granuloma annulare, opportunistic infections), history of episodes of hypoglycemia, diabetic ketoacidosis and/or hyperosmolar coma.
• •History of reaction to liquid dressings.
• •Known hypersensitivity to any ingredients of investigational product formulation.
• •Other diseases or use of drugs that may directly interfere with the study or put the research participant's health at risk.
• •Presence of any serious or uncontrolled diseases, at the investigator's discretion.
• •Pregnancy or lactation.
• •Participation in a clinical research protocol in the last 12 months, unless, at the investigator's discretion, their participation in the study may result in direct benefit to the participant.
• •Presence of any conditions that, at the investigator's discretion, make the participant unable to participate in the study.